PMID- 30249615
DCOM- 20190315
LR  - 20190315
IS  - 1756-1833 (Electronic)
IS  - 0959-8138 (Linking)
VI  - 362
DP  - 2018 Sep 24
TI  - Challenges of independent assessment of potential harms of HPV vaccines.
PG  - k3694
LID - 10.1136/bmj.k3694 [doi]
FAU - Jorgensen, Lars
AU  - Jorgensen L
AD  - Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
FAU - Doshi, Peter
AU  - Doshi P
AD  - University of Maryland School of Pharmacy, Baltimore, Maryland, USA.
FAU - Gotzsche, Peter
AU  - Gotzsche P
AD  - Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
FAU - Jefferson, Tom
AU  - Jefferson T
AD  - Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20180924
PL  - England
JT  - BMJ (Clinical research ed.)
JID - 8900488
RN  - 0 (Papillomavirus Vaccines)
SB  - IM
MH  - Female
MH  - Humans
MH  - Papillomavirus Infections/*prevention & control
MH  - Papillomavirus Vaccines/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk Assessment
MH  - Uterine Cervical Neoplasms/*prevention & control
MH  - Vaccination/*adverse effects
COIS- Competing interests: We have read and understood BMJ policy on declaration of
      interests and declare the following interests. PD and TJ are recipients of a
      grant from the Laura and John Arnold Foundation to run a RIAT Support Center and 
      were corecipients of a UK National Institute for Health Research grant
      (HTA-10/80/01 Update and amalgamation of two Cochrane reviews: neuraminidase
      inhibitors for preventing and treating influenza in healthy adults and children).
      They are also in receipt of a Cochrane Methods Innovations Fund grant to develop 
      guidance on the use of regulatory data in Cochrane reviews. PD sued the attorney 
      general of Canada to get access to data on HPV vaccines. He has received funding 
      from the American Association of Colleges of Pharmacy for a study to analyse
      written medical information on the possible harms of statins. PD is also an
      associate editor of The BMJ and an unpaid member of the IMEDS steering committee 
      at the Reagan-Udall Foundation for the FDA, which focuses on drug safety
      research. TJ is occasionally interviewed by market research companies about phase
      I or II drugs. He has acted as an expert witness in litigation cases related to
      the antiviral oseltamivir and influenza vaccines and been a scientific adviser to
      a legal team acting on oseltamivir. TJ was a member of three advisory boards for 
      Boerhinger Ingelheim and a member of an independent data monitoring committee for
      a Sanofi Pasteur clinical trial of an influenza vaccine. From 1994 to 2013, TJ
      was the coordinator of the Cochrane Vaccines Field. He is coholder of a Jean
      Monnet Network Grant. He is an unpaid collaborator to the project Beyond
      Transparency in Pharmaceutical Research and Regulation led by Dalhousie
      University and funded by the Canadian Institutes of Health Research. LJ and PCG
      have no competing interests to declare.
EDAT- 2018/09/27 06:00
MHDA- 2019/03/16 06:00
CRDT- 2018/09/26 06:00
PHST- 2018/09/26 06:00 [entrez]
PHST- 2018/09/27 06:00 [pubmed]
PHST- 2019/03/16 06:00 [medline]
AID - 10.1136/bmj.k3694 [doi]
PST - epublish
SO  - BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694.